FI107994B - Menetelmä L-DOPA:n etyyliesteriä sisältävän koostumuksen valmistamiseksi - Google Patents

Menetelmä L-DOPA:n etyyliesteriä sisältävän koostumuksen valmistamiseksi Download PDF

Info

Publication number
FI107994B
FI107994B FI935847A FI935847A FI107994B FI 107994 B FI107994 B FI 107994B FI 935847 A FI935847 A FI 935847A FI 935847 A FI935847 A FI 935847A FI 107994 B FI107994 B FI 107994B
Authority
FI
Finland
Prior art keywords
dopa
ethyl ester
composition
base
solution
Prior art date
Application number
FI935847A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI935847A0 (fi
FI935847A (fi
Inventor
Isaac Milman
Alexander Veinberg
Daphne Atlas
Eldad Melamed
Original Assignee
Teva Pharma
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma
Publication of FI935847A0 publication Critical patent/FI935847A0/fi
Publication of FI935847A publication Critical patent/FI935847A/fi
Application granted granted Critical
Publication of FI107994B publication Critical patent/FI107994B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FI935847A 1992-12-24 1993-12-23 Menetelmä L-DOPA:n etyyliesteriä sisältävän koostumuksen valmistamiseksi FI107994B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA
US99584792 1992-12-24

Publications (3)

Publication Number Publication Date
FI935847A0 FI935847A0 (fi) 1993-12-23
FI935847A FI935847A (fi) 1994-06-25
FI107994B true FI107994B (fi) 2001-11-15

Family

ID=25542272

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935847A FI107994B (fi) 1992-12-24 1993-12-23 Menetelmä L-DOPA:n etyyliesteriä sisältävän koostumuksen valmistamiseksi

Country Status (21)

Country Link
US (2) US5354885A (no)
EP (2) EP0867179B1 (no)
JP (1) JPH07285860A (no)
CN (1) CN1083262C (no)
AT (2) ATE178793T1 (no)
AU (1) AU684053B2 (no)
CA (1) CA2112160A1 (no)
CY (1) CY2214B1 (no)
DE (2) DE69329400T2 (no)
DK (2) DK0610595T3 (no)
ES (2) ES2150294T3 (no)
FI (1) FI107994B (no)
GR (2) GR3030073T3 (no)
HK (1) HK1012577A1 (no)
HU (1) HU218906B (no)
IL (1) IL108147A (no)
LV (1) LV12766B (no)
NO (1) NO305932B1 (no)
NZ (1) NZ250541A (no)
PT (1) PT867179E (no)
ZA (1) ZA939573B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
AU7669496A (en) * 1995-11-03 1997-05-22 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
WO1997017067A1 (en) * 1995-11-06 1997-05-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
DE69902520T2 (de) 1998-03-16 2003-04-10 Somerset Pharmaceuticals, Inc. Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
US6376545B1 (en) * 1998-11-10 2002-04-23 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing L-DOPA ethyl ester
CA2350303A1 (en) * 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Process for manufacture of l-dopa ethyl ester
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030135065A1 (en) * 2001-11-13 2003-07-17 Ramy Lidor-Hadas Process for the production of L-DOPA ethyl ester
AU2002340470A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
WO2003079992A2 (en) 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Pulmonary delivery for levodopa
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
JP2006524708A (ja) * 2003-04-25 2006-11-02 インディヴァス ファーマシューティカルズ，インコーポレーテッド 塩化トロスピウムの投与により連続睡眠を促進するための方法
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
CA2540052C (en) * 2003-10-08 2012-04-10 Mallinckrodt Inc. Methylphenidate solution and associated methods of administration and production
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
EA017983B1 (ru) * 2006-02-17 2013-04-30 Бедс Фарма Гмбх Беролина Инновейтив Ресёч Энд Девелопмент Сёвисиз Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
AU2016313138A1 (en) * 2015-08-27 2018-03-15 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
US20190224153A1 (en) 2016-09-29 2019-07-25 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
PL4039093T3 (pl) 2021-02-09 2024-02-05 Biobab R&D, S.L. Sposób i zastosowanie enancjomerów 3,4-dihydroksyfenyloalaniny (DOPA) do wzmagania atrakcyjności rośliny dla owadów pożytecznych

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
EP0252290B1 (en) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof

Also Published As

Publication number Publication date
LV12766B (en) 2002-03-20
DE69329400D1 (de) 2000-10-12
HK1012577A1 (en) 1999-08-06
EP0610595A3 (en) 1994-09-21
EP0610595B1 (en) 1999-04-14
IL108147A (en) 1998-09-24
HU218906B (hu) 2000-12-28
DE69329400T2 (de) 2001-01-18
NO934768D0 (no) 1993-12-22
JPH07285860A (ja) 1995-10-31
ATE196081T1 (de) 2000-09-15
CN1094950A (zh) 1994-11-16
PT867179E (pt) 2000-12-29
GR3034867T3 (en) 2001-02-28
DE69324466D1 (de) 1999-05-20
US5525631A (en) 1996-06-11
HU9303748D0 (en) 1994-04-28
AU684053B2 (en) 1997-12-04
ATE178793T1 (de) 1999-04-15
DE69324466T2 (de) 1999-11-25
LV12766A (lv) 2001-12-20
CY2214B1 (en) 2002-11-08
FI935847A0 (fi) 1993-12-23
HUT68498A (en) 1995-06-28
EP0867179B1 (en) 2000-09-06
DK0610595T3 (da) 1999-10-25
NZ250541A (en) 1995-12-21
NO305932B1 (no) 1999-08-23
EP0867179A1 (en) 1998-09-30
EP0610595A2 (en) 1994-08-17
US5354885A (en) 1994-10-11
DK0867179T3 (da) 2000-11-06
AU5257793A (en) 1994-07-07
GR3030073T3 (en) 1999-07-30
ES2150294T3 (es) 2000-11-16
NO934768L (no) 1994-06-27
CA2112160A1 (en) 1994-06-25
IL108147A0 (en) 1994-04-12
CN1083262C (zh) 2002-04-24
ES2132170T3 (es) 1999-08-16
FI935847A (fi) 1994-06-25
ZA939573B (en) 1994-08-11

Similar Documents

Publication Publication Date Title
FI107994B (fi) Menetelmä L-DOPA:n etyyliesteriä sisältävän koostumuksen valmistamiseksi
US5607969A (en) L-DOPA ethyl ester to treat Parkinson's disease
RU2128160C1 (ru) Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция
EP1991522B1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
JPH06505241A (ja) 選択性ｍａｏ−ｂ抑制薬および神経保護薬としての脂肪族プロパルギルアミン
WO2019038638A1 (en) PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA
CA3102106A1 (en) Methods for increasing sepiapterin plasma exposure
JPH09511516A (ja) グルカミン誘導体を用いるエトドラックの分割法
IL169203A (en) History of catecholamines that have passed through the deuterium, pharmaceutical preparations containing them and drugs containing them or their mixtures together with enzyme inhibitors
EP1061909B1 (fr) Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
US7786168B2 (en) Phenolic acid salts of gabapentin in solid dosage forms and methods of use
US20100069450A1 (en) Salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7, 7a- octahydrobenzo[d]isoxazol-4-one
HRP20040560A2 (en) Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds
FR2499981A1 (fr) Acides amino-2 halogenobenzoyl-3 methylphenylacetiques et leurs esters et sels utiles comme medicaments anti-inflammatoires et analgesiques
WO2020035853A1 (en) Process for preparing purified levodopamide free base
HU210203A9 (hu) Lényegesen kevesebb gasztrointesztinális irritációt és fekélyképződést okozó ketorolak-származékok Az átmeneti oltalom az 1-2.. igénypontra vonatkozik.
FR2506765A1 (fr) Aryl carboxamides de la pyrrolidino ethylamine, leur preparation et leur application en tant que medicaments antitussifs
ITRM970176A1 (it) Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine
BE859323A (fr) Nouveau derive de la morphanthridine et son application comme medicament
JPH03376B2 (no)

Legal Events

Date Code Title Description
MA Patent expired